{"prompt": "['57', 'MC1488 WEE1', 'MCCC', 'major CYP isoform involved in the oxidative metabolism of AZD1775, to', 'the N-demethylated product. In addition, studies with flavin-containing', 'monooxygenase (FMO) enzymes indicated that FMO3 and FMO5 were', 'involved in formation of the N-oxide derivative of AZD1775.', '15.16', 'Potential Drug Interactions: The following treatments and all the medications listed in', 'Appendix VI are prohibited while in this study. Any further questions regarding concomitant', 'treatments should be referred to the sponsor:', 'No other investigational therapy should be given to patients. No anticancer agents other than the', 'study medications should be given to patients. If such agents are required for a patient, then the', 'patient must first be withdrawn from the study.', 'No formal clinical drug interaction studies have been performed with AZD1775. An exploratory', 'assessment of the effect of aprepitant on AZD1775 exposure in oncology patients suggests that', 'there is a drug interaction between AZD1775 and aprepitant, as exposure to AZD1775 increased', 'by ~60% when aprepitant was co-administered with AZD1775. The observed increase in', 'AZD1775 exposure is likely the result of CYP3A4 inhibition by aprepitant. This increase in', 'exposure is statistically significant. At the selected MTDs, this increase may also be of clinical', 'importance. Therefore, concomitant treatment with aprepitant and fosaprepitant is not allowable', 'per protocol until further evaluation.', 'Potent or moderate inhibitors or inducers of CYP3A4, sensitive CYP3A4 substrates, and', 'CYP3A4 substrates with a narrow therapeutic window should be avoided until additional data on', 'drug-drug interaction becomes available (Appendix VI).', 'In vitro data suggests that AZD1775 may also be a weak reversible inhibitor of CYP2C19.', 'Caution should be exercised with concomitant administration of AZD1775 and agents that are', 'sensitive substrates of CYP2C19, or substrates of this enzyme with narrow therapeutic range;', 'refer to Appendix VI for a list of sensitive substrates of CYP2C19, or substrates of this enzyme', 'with narrow therapeutic range.', 'AZD1775 has been shown to be a weak inducer of CYP1A2 in vitro with a maximum measured', 'response between donors of 39.9% to 93.1% (at 10 M) and 18.6% to 32.5% (at 5 M) of the', 'positive control omeprazole (50 M), respectively. Given the nature of the AZD1775 dosing', 'schedule, however, the risk of induction in the clinic is considered low. No specific precautions', 'are recommended at this time, except to be initially vigilant when using substrates of CYP1A2', 'with a narrow therapeutic range.', 'In vitro studies have shown that AZD1775 may be a substrate and inhibitor for human', 'P-glycoprotein (P-gp). Caution should be exercised when agents that are inhibitors or substrates', 'of P-gp are administered concomitantly with AZD1775 (see Appendix VI).', 'Recent in vitro transporter studies have shown AZD1775 to be an inhibitor of BCRP (IC50 5.1', 'M). This finding is particularly relevant for drugs administered orally where exposure is', 'normally limited by BCRP-mediated efflux, in particular some statins. Modelling has predicted a', 'substantial increase in the exposure of Atorvastatin when co-administered with AZD1775 and the']['58', 'MC1488 WEE1', 'MCCC', 'use of Atorvastatin is therefore prohibited in the current study. Other drugs where the', 'disposition is mediated via BCRP should be administered with caution, dose modification', 'considered or substituted by an alternative drug (Appendix VI).', 'AZD1775 has been shown to be an inhibitor or MATE1 and MATE2K transporters. A drug', 'interaction with substrates of either transporter cannot be ruled out, the most important substrate', 'known to date being metformin.', 'Herbal preparations/medications are not allowed throughout the study. These herbal medications', \"include, but are not limited to: St. John's wort, kava, ephedra (ma huang), gingko biloba,\", 'dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng. Patients should stop', 'using these herbal medications 14 days prior to first dose of AZD1775.', '15.17 Known potential toxicities: Based on the preliminary safety data', 'available, the most frequent adverse events observed were blood and', 'lymphatic disorders (anemia, febrile neutropenia), gastrointestinal', 'disorders (diarrhea, vomiting, nausea, abdominal pain, constipation),', 'general disorders and administration site conditions (fatigue, fever, chills),', 'and investigation findings (thrombocytopenia, neutropenia, hematology', 'and serum chemistry).', '15.18', 'Drug procurement: Drug will be provided by AstraZeneca.', '15.2', 'Cytarabine (AraC)', '15.21', 'Background: Cytarabine (cytosine arabinoside) inhibits DNA synthesis.', 'Cytosine gains entry into cells by a carrier process, and then must be converted to', 'its active compound, aracytidine triphosphate. Cytosine is a pyrimidine analog', 'and is incorporated into DNA; however, the primary action is inhibition of DNA', 'polymerase resulting in decreased DNA synthesis and repair. Cytarabine is', 'specific for the S phase of the cell cycle (blocks progression from the G1 to the', 'S', 'phase).', '15.22', 'Formulation: Commercially available for injection, powder for reconstitution:', '100 mg, 500 mg, 1 gram, 2 gram', '15.23', 'Preparation, storage, and stability: Store intact vials of powder at room', 'temperature 15\u00b0C to 30\u00b0C (59\u00b0F to 86\u00b0F). Reconstitute with bacteriostatic', 'water for injection. Reconstituted solutions are stable for up to 8 days at', 'room temperature, although the manufacturer recommends use within 48', 'hours. Further dilution in 250-1000 mL of D5W or 0.9% NaCL is stable', 'for 8 days at room temperature (25C). Note: Solutions containing']\n\n###\n\n", "completion": "END"}